Proactive Investors - Run By Investors For Investors

eWellness Healthcare to bring at-home physical therapy to Texas smartphone users

The Texas Board of Physical Therapy Examiners has included telehealth as a treatment option
Doctor on a smartphone
eWellness operates the Phzio platform, which provides telehealth physical therapy

eWellness Healthcare Corporation (OTCQB:EWLL) is bringing new treatment options to patients in need of physical therapy in Texas.

The Texas Board of Physical Therapy Examiners has included telehealth as a treatment option to patients physically located in the state.

READ: Q BioMed’s Metastron acquisition ‘positive development,’ advances pipeline, says Brookline Capital Markets

Its Phzio platform offers insurance reimbursable telehealth physical therapy that can be accessed via a smartphone.

Patients can start a video call to receive a diagnosis and a treatment plan.

"We have created a strong path to lowering the spending on physical therapy claims through the utilization of our PHZIO digital PT treatment platform and are happy to be in a position to share our revolutionary cost savings technology with patients in the great state of Texas,” said CEO Darwin Fogt in the company’s press release.

Fogt is hopeful that use of the platform will lower patient treatment costs, expand access to treatment and improve patient compliance.

The company values the physical therapy market at $30 billion.

Shares of the California-based company were up 7% to $0.20 in Tuesday trading.


Contact Lenore Fedow at [email protected]

Follow her on Twitter@LenoreMariee

View full EWLL profile View Profile

eWellness Healthcare Corp. Timeline

Related Articles

November 14 2018
The goal of the program is to extend the visualization extracted from 2D ultrasound images and visualize 4D images
September 27 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability
cancer scan
January 03 2019
The company, which owns a piece of software which predicts the effects of drugs on cancers, has recently extended a lucrative agreement with German firm Merck Serono while it has also signed a strategic collaboration with the Medicines Discovery Catapult
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use